Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry - Takeaways - MDSpire

Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry

  • By

  • Marisa Iborra

  • Berta Caballol

  • Alejandro Garrido

  • José María Huguet

  • Francisco Mesonero

  • Ángel Ponferrada

  • Lara Arias García

  • Marta Maia Boscá Watts

  • Samuel J Fernández Prada

  • Eduard Brunet Mas

  • Ana Gutiérrez Casbas

  • Elena Cerrillo

  • Ingrid Ordás

  • Lucía Ruiz

  • Irene García de la Filia

  • Jaime Escobar Ortiz

  • Beatriz Sicilia

  • Elena Ricart

  • Eugeni Domènech

  • Pilar Nos

  • August 22, 2024

  • 0 min

Share

  • 1

    Switching from intravenous infliximab to subcutaneous infliximab safely maintains clinical remission in patients with Crohn's disease and ulcerative colitis.

  • 2

    The study included 220 patients, with 66% having Crohn's disease and 34% having ulcerative colitis, all in clinical remission for at least 24 weeks.

  • 3

    Subcutaneous infliximab levels significantly increased post-switch, with optimal cutoff concentrations for remission identified as 12-13 μg/mL.

  • 4

    Drug persistence at Week 52 was 92%, indicating a favorable long-term safety profile for subcutaneous infliximab.

  • 5

    Higher body mass index was associated with increased infliximab trough levels, while immunomodulatory therapy did not affect these levels.

Original Source(s)

Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry

  • by Marisa Iborra, Berta Caballol, Alejandro Garrido, José María Huguet, Francisco Mesonero, Ángel Ponferrada, Lara Arias García, Marta Maia Boscá Watts, Samuel J Fernández Prada, Eduard Brunet Mas, Ana Gutiérrez Casbas, Elena Cerrillo, Ingrid Ordás, Lucía Ruiz, Irene García de la Filia, Jaime Escobar Ortiz, Beatriz Sicilia, Elena Ricart, Eugeni Domènech, Pilar Nos

  • August 22, 2024

Related Content

Genes Predict Bowel Disease Severity

Large study suggests genetic risk scores could help doctors identify patients who need closer monitoring and earlier treatment

  • March 12, 2026

  • 2 min
Evaluation of 5-Aminosalicylic Acid Utilization in Crohn’s Disease Management: Insights from a Nationwide Survey of Inflammatory Bowel Disease Specialists

Case Report: Bilateral panuveitis with serous ciliary body and choroidal detachment associated with ulcerative colitis